Why is "Anidulafungin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-06 03:13:21
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Anidulafungin (INN) (sold under the brand name Eraxis among others, is a semisynthetic echinocandin used as an antifungal medication. It may also have application in treating invasive Aspergillus infection when used in combination with voriconazole. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of -β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Candida parapsilosis and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel? - ASM Journals
-
APMIS | Medical Research Journal - Wiley Online Library
-
Endopharm has registered Russia’s new antifungal drug - Новости GxP
-
FKS1 mutation associated with decreased echinocandin susceptibility of Aspergillus fumigatus following anidulafungin exposure - Nature
-
Anidulafungin versus Fluconazole for Invasive Candidiasis - NEJM
-
Tolerance to drugs from echinocandin class: caspofungin, anidulafungin and micafungin - University of Rochester Medical Center
-
Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction - Frontiers
-
Echinocandin Dosing Considerations in Obese Patients: A Review - Contagion Live
-
Antifungal Susceptibility Testing for C. auris - Centers for Disease Control and Prevention | CDC (.gov)
-
Synergy, Indifference, or Antagonism? In Vitro Susceptibility of Fusarium and Aspergillus spp Isolated From Keratitis in South India Against Combinations of Natamycin, Voriconazole, and Anidulafungin | IOVS | ARVO Journals - ARVO Journals
-
Managing Candida auris fungemias: the results of a prospective and international study - ASM Journals
-
Anidulafungin versus Fluconazole for Invasive Candidiasis - NEJM
-
Evaluation of the in vitro Activity and in vivo Efficacy of Anidulafungin-Loaded Human Serum Albumin Nanoparticles Against Candida albicans - Frontiers
-
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
-
A Long-Acting Injectable for the Treatment of Candida spp Infections - Contagion Live
-
Notes from the Field : Surveillance for Candida auris — Colombia, September 2016–May 2017 - Centers for Disease Control and Prevention | CDC (.gov)
-
Clinical and Laboratory Development of Echinocandin Resistance in Candida glabrata: Molecular Characterization - Frontiers
-
Diagnosis and Treatment Challenges of Candida guilliermondii in Immunocompromised Patients: A Case Study in a Neutropenic AML Patient - Wiley Online Library
-
Reshaping Echinocandin Antifungal Drugs To Circumvent Glucan Synthase Point-Mutation-Mediated Resistance - Wiley Online Library
-
Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS - Frontiers
-
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023 - BioSpace
-
Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia - Nature
-
Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database - Frontiers
-
Unlocking New Defenses: The Changing Landscape of Candida auris Management - Contagion Live
-
Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata - Nature
-
Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species - ASM Journals
-
Adverse Effects Associated With Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review - Frontiers
-
Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates - Nature
-
CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility - Nature
-
ATR-FTIR spectroscopic markers indicating drug resistance in selected Candida strains - Nature
-
Global Surge in Candida Infections Spurs New Treatment Guidelines - Medscape
-
Candida Species and Antifungal Resistance in Clinical Isolates - Physician's Weekly
-
Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: a comprehensive review - Frontiers
-
How to improve antifungal stewardship - The Pharmaceutical Journal
-
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks - BioSpace
-
The challenge of systemic Candida infections - Hospital Pharmacy Europe
-
Candidiasis: New agents for invasive infections - Clinical Advisor
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.